Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia - 1 Apr 2024

Rajakumaraswamy Nishanthan, Gandhi Mitul, Wei Andrew H, Sallman David A, Daver Naval G, Mo Shuyuan, Iqbal Shahed, Karalliyadda Roshan, Chen Manli, Wang Yunfei, Vyas Paresh

Abstract excerpt

INTRODUCTION: Azacitidine (AZA) is an approved frontline therapy for higher-risk myelodysplastic syndromes (HR-MDS); however, poor survival denotes unmet needs to increase depth/duration of response (DOR). METHODS: This retrospective study with patient chart review evaluated AZA effectiveness in 382 treatment-naive patients with HR-MDS from a US electronic health record (EHR)-derived database. Responses were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Treatment Outcome

Source

Identifiers

PMID: 38216397
DOI: 10.1016/j.clml.2023.12.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.PMID 38216397Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Survival of myelodysplastic syndrome patients after azacitidine therapy.Semantic proximity Read ↗

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Semantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaSemantic proximity Read ↗

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM studySemantic proximity Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesSemantic proximity Read ↗

Translational Research on Azacitidine Post- Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.